

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Assessing Efficacy and Safety of a Novel Low-Dose Turmeric Extract Formulation in Healthy Adults with Chronic Knee Pain [Corrigendum]

Thanawala S, Shah R, Somepalli V, Alluri KV, Desomayanandam P, Bhuvanendran A. *Clin Pharmacol*. 2021;13:91–100.

The authors have informed the journal that on page 93, Table 2 “Efficacy Endpoints”, for the primary endpoint “Visual analogue scale after 80-m fast-paced walk test”, the parameter “Change from B to D45” is erroneously mentioned as -1.5 ± 0.4 where it should be -1.0 ± 0.4 .

The correct Table 2 is:

On page 96, Table 3 “Biochemical and Inflammatory Markers”, for C-reactive protein, the unit is erroneously mentioned as (mg/dL), where it should be (mg/L).

The correct Table 3 is:

The authors advise these errors/corrections will not affect the previously shown results/conclusions and apologize for any confusion this may have caused.

Table 2 Efficacy Endpoints

	WDTE60N (n = 49)		Placebo (n = 47)		p-value
	Mean ± SD	Median (IQR)	Mean ± SD	Median (IQR)	
Visual analogue scale after 80-m fast-paced walk test					
Baseline	5.4 ± 0.9	5 (5, 6)	5.4 ± 0.8	5 (5, 6)	< 0.0001*
Day 45	4.4 ± 0.8	4 (4, 5)	4.9 ± 0.6	5 (5, 5)	
Day 90	3.8 ± 0.8	4 (3, 4)	4.8 ± 0.6	5 (4.3, 5)	
Change from B to D45	-1.0 ± 0.4	-1 (-1, -1)	-0.4 ± 0.6	0 (-1, 0)	
Change from B to D90	-1.5 ± 0.7	-2 (-2, -1)	-0.6 ± 0.8	0 (-1, 0)	
80 m- fast-paced walk test (s)					
Baseline	70.3 ± 23.9	60.1 (59.1, 60.5)	69.2 ± 23.4	60.08 (57.7, 60.3)	0.0002*
Day 45	65.2 ± 18.8	60.0 (58.9, 60.1)	62.9 ± 15.2	60.04 (57.8, 60.2)	
Day 90	59.3 ± 9.5	59.8 (57.3, 60.1)	62.4 ± 15.4	60.0 (57.4, 60.1)	
Change from B to D45	-5.0 ± 16.5	-0.09 (-0.3, -0.04)	-6.3 ± 18.6	0.0 (-0.07, 0.07)	
Change from B to D90	-11.0 ± 26.1	-0.2 (-2, -0.06)	-6.8 ± 23.3	0 (-0.2, 0.2)	
9-step stair climb test (s)					
Baseline	49.2 ± 40.9	60.2 (10.8, 60.5)	44.8 ± 39.2	60.2 (10.6, 60.5)	< 0.0001*
Day 45	40.2 ± 29.7	60.0 (10.6, 60.2)	39.9 ± 32.1	60.1 (10.8, 60.2)	
Day 90	36.9 ± 24.3	52.0 (10.5, 60.1)	37.0 ± 27.6	52 (10.8, 60.1)	
Change from B to D45	-8.9 ± 21.0	-0.1 (-0.4, -0.07)	-4.9 ± 21.0	0.04 (-0.07, 0.09)	
Change from B to D90	-12.3 ± 24.2	0.2 (-0.8, -0.1)	-7.8 ± 24.2	0.04 (-0.2, 0.1)	

(Continued)

Table 2 (Continued).

	WDTE60N (n = 49)		Placebo (n = 47)		p-value
	Mean ± SD	Median (IQR)	Mean ± SD	Median (IQR)	
Primary knee flexion (degree)					
Baseline	134.2 ± 0.9	134 (134, 135)	134.4 ± 0.9	134 (134, 135)	0.3657
Day 45	134.1 ± 0.6	134 (134, 134)	134.3 ± 0.8	134 (134, 135)	
Day 90	134.0 ± 0.6	134 (134, 134)	134.3 ± 0.7	134 (134, 134)	
Change from B to D45	−0.1 ± 0.7	0 (0, 0)	−0.0 ± 0.5	0 (0, 0)	
Change from B to D90	−0.2 ± 0.6	0 (0, 0)	−0.1 ± 0.8	0 (0, 0)	

Note: *p-value less than 0.05 ($p \leq 0.05$) is statistically significant.

Abbreviations: B to D, baseline to day; IQR, interquartile range.

Table 3 Biochemical and Inflammatory Markers

	WDTE60N (n = 49)		Placebo (n = 47)		p-value*
	Mean ± SD	Median (IQR)	Mean ± SD	Median (IQR)	
C-reactive protein (mg/L)					
Baseline	5.3 ± 14.0	1.7 (0.9, 4.8)	3.0 ± 3.6	1.6 (0.8, 3.4)	0.2868
Day 90	2.6 ± 2.6	1.6 (0.9, 3.4)	9.5 ± 26.8	1.9 (1, 4)	
Change from B to D90	-2.7 ± 14.5	-0.2 (-1.5, 1.1)	6.5 ± 26.7	0.0 (-0.8, 1.4)	
p-value**	0.2327		0.2676		
Interleukin 6 (pg/mL)					
Baseline	21.1 ± 31.3	8.1 (0.07, 29.7)	20.5 ± 36.3	3.3 (0.07, 18.4)	0.1699
Day 90	30.5 ± 52.6	4.1 (0.7, 26.7)	26.8 ± 40.2	8.3 (1, 31.7)	
Change from B to D90	9.4 ± 62.7	0.5 (-19, 12.8)	6.3 ± 36.6	3.1 (-0.79, 22.6)	
p-value**	0.4641		0.0188		
Tumor necrosis factor-α (pg/mL)					
Baseline	30.4 ± 52.5	2.6 (0.2, 48.8)	31.6 ± 60.6	0.7 (0.1, 34.4)	0.0927
Day 90	14.9 ± 45.1	0.7 (0.7, 0.7)	22.4 ± 32.6	0.7 (0.7, 30.7)	
Change from B to D90	-15.5 ± 67.1	-0.2 (-24.9, 0.6)	-9.3 ± 67.3	0.5 (-20.6, 12.4)	
p-value**	0.0054		0.4522		
Matrix metalloproteinase-3 (ng/mL)					
Baseline	20.9 ± 15.4	19.7 (6.6, 35.0)	18.9 ± 16.6	12.5 (5.5, 34.2)	0.1387
Day 90	14.1 ± 9.4	12.5 (6.6, 19.6)	15.9 ± 9.7	13 (7.7, 23.5)	
Change from B to D90	-6.8 ± 14.9	-7 (-15.7, 2.5)	-3.0 ± 14	-0.4 (-9.4, 5.7)	
p-value**	0.0017		0.1335		

Notes: *p-value from the Mann-Whitney U-test comparing the difference between placebo versus WDTE60N; **p-value from Wilcoxon signed-rank test comparing levels at baseline to day 90.

Abbreviations: B to D, baseline to day; IQR, interquartile range.

Clinical Pharmacology: Advances and Applications

Dovepress

Publish your work in this journal

Clinical Pharmacology: Advances and Applications is an international, peer-reviewed, open access journal publishing original research, reports, reviews and commentaries on all areas of drug experience in humans. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/clinical-pharmacology-advances-and-applications-journal>